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ABSTRACT
EGFR mutated lung cancer accounts for a significant subgroup of non-small-cell 
lung cancer (NSCLC). Over the last decade, multiple EGFR tyrosine kinase inhibitors 
(EGFR-TKIs) have been developed to target mutated EGFR. However, there is little 
information regarding mutation specific potency of EGFR-TKIs against various types 
of EGFR mutations. The purpose of this study is to establish an in vitro model to 
determine the “therapeutic window” of EGFR-TKIs against various types of EGFR 
mutations, including EGFR exon 20 insertion mutations. The potency of 1st (erlotinib), 
2nd (afatinib) and 3rd (osimertinib and rociletinib) generation EGFR-TKIs was compared 
in vitro for human lung cancer cell lines and Ba/F3 cells, which exogenously express 
mutated or wild type EGFR. An in vitro model of mutation specificity was created by 
calculating the ratio of IC50 values between mutated and wild type EGFR. The in vitro 
model identified a wide therapeutic window of afatinib for exon 19 deletions and 
L858R and of osimertinib and rociletinib for T790M positive mutations. The results 
obtained with our models matched well with previously reported preclinical and 
clinical data. Interestingly, for EGFR exon 20 insertion mutations, most of which are 
known to be resistant to 1st and 2nd generation EGFR-TKIS, osimertinib was potent 
and presented a wide therapeutic window. To our knowledge, this is the first report 
that has identified the therapeutic window of osimertinib for EGFR exon 20 insertion 
mutations. In conclusion, this model will provide a preclinical rationale for proper 
selection of EGFR-TKIs against clinically-relevant EGFR mutations.
INTRODUCTION
Lung cancer is the leading cause of cancer related 
death worldwide [1]. The identification of somatic 
mutations within the epidermal growth factor receptor 
(EGFR) kinase domain helped our understanding of the 
biology of lung cancer harboring EGFR mutations [2–6]. 
EGFR mutations are expected to activate the EGFR by 
destabilizing the inactive form of EGFR without ligand 
stimulation [7–9]. Activated EGFR induces EGFR-
mediated pro-survival and anti-apoptotic signals through 
downstream targets such as extracellular-signal-regulated 
kinase (ERK)/mitogen-activated protein kinase (MAPK) 
and phosphatidylinositol-3-kinases (PI3K)/protein kinase 
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B (AKT) [10, 11]. Inhibition of the EGFR pathway leads 
to the down-regulation of pro-survival signals and up-
regulation of pro-apoptotic molecules [12], by which 
EGFR tyrosine kinase inhibitors (EGFR-TKIs) exert their 
dramatic effects in patients with EGFR mutated lung 
cancer.
EGFR mutations have been identified in 
approximately 10–30% of non-small-cell lung cancer 
(NSCLC) [13, 14]. The most common, “classic” mutations 
are in-frame deletions around the LREA motif of exon 
19 (approximately 45% of EGFR mutations) and the 
exon 21 L858R point mutation (approximately 40% of 
EGFR mutations). Other relatively rare EGFR mutations 
include, G719X (3% of EGFR mutations) and L861Q (2% 
of EGFR mutations) [10]. Another main group of EGFR 
mutations include exon 20 insertion mutations (4–10% of 
EGFR mutations) [15, 16].
EGFR tyrosine kinase inhibitors (EGFR-TKIs) 
have been developed to target mutated EGFR. EGFR-
TKIs reversibly or irreversibly bind to the ATP binding 
pocket of EGFR and inhibit the phosphorylation of EGFR, 
thereby inhibiting the activation of the EGFR signaling 
pathway. The exon 19 deletions, L858R, G719X, and 
L861Q mutations are 1st generation EGFR-TKIs, gefitinib 
and erlotinib, sensitizing mutations. The response rates to 
gefitinib or erlotinib are around 60–80% [14, 17].
Most EGFR exon 20 insertion mutations are 1st 
generation EGFR-TKIs resistant mutations [15, 18, 19]. 
One exception is EGFR A763_Y764insFQEA, which 
we previously reported as another 1st generation EGFR-
TKIs sensitizing mutation [20]. For these 1st generation 
EGFR-TKIs resistant exon 20 insertion mutations, no 
potent inhibitor has been reported. Therefore, patients 
with NSCLC harboring EGFR exon 20 insertion mutations 
present a shorter survival time compared to patients 
with classic EGFR mutations [21]. The development of 
EGFR-TKIs, which effectively inhibit EGFR with exon 
20 insertions, but not the wild type EGFR, has been 
anticipated.
The 1st generation reversible EGFR-TKIs, gefitinib 
and erlotinib, dramatically changed the treatment strategy 
for patients harboring EGFR mutated lung cancer. The 
significant benefit of gefitinib or erlotinib for patients with 
NSCLC harboring EGFR-TKIs sensitizing mutations was 
repeatedly demonstrated in multiple clinical trials [22, 23]. 
However, despite the initial favorable response, lung 
cancer cells eventually acquire resistance to gefitinib or 
erlotinib. EGFR T790M mutations account for about 50% 
of acquired resistance to gefitinib or erlotinib [24, 25]. 
To target EGFR mutations, including EGFR T790M 
mutation, multiple EGFR-TKIs have been developed. 
These include 2nd generation EGFR-TKIs, afatinib [26] 
and dacomitinib [27, 28], as well as 3rd generation EGFR-
TKIs, WZ4002 [29], osimertinib (formerly AZD9291) 
[30, 31] and rociletinib [32, 33].
Afatinib, a clinically available 2nd generation 
EGFR-TKI, is potent against EGFR mutated lung cancer 
cells in vitro [26] and in vivo [34, 35]. However, for 
EGFR T790M mutated lung cancer, it failed to overcome 
EGFR T790M-mediated resistance in patients [36, 37]. 
Osimertinib and rociletinib are 3rd generation EGFR-
TKIs, both of which are reported to be effective in lung 
cancer cells harboring EGFR T790M in preclinical 
models [30, 32]. Promising results of phase I/II study of 
osimertinib and rociletinib have recently been published. 
Osimertinib showed a promising safety and efficacy, the 
response rate and progression free survival for EGFR 
T790M positive patients was 61% and 9.6 months, 
respectively [38]. Similarly, the response rate of rociletinib 
for EGFR T790M positive patients was 59% [39].
Today, we have multiple EGFR-TKI options to treat 
patients with lung cancer harboring EGFR mutations. 
However, there is no clear guideline regarding which 
EGFR-TKIs should be used for which mutation. To 
solve this problem and provide a model, which clinicians 
or physician scientists could refer to, we examined and 
compared the potency of EGFR-TKIs against lung cancer 
cell lines harboring various types of EGFR mutations. 
In addition, we created an in vitro model, which allows 
us to determine the therapeutic window of EGFR-TKIs. 
This model will provide a preclinical rationale for proper 
selection of EGFR-TKIs against clinically-relevant EGFR 
mutations.
RESULTS
Comparison of the sensitivity/resistance profile 
of Ba/F3 stable cell lines
In order to directly compare the sensitivity of 
multiple EGFR mutations to EGFR-TKIs, we generated 
EGFR transduced Ba/F3 stable cell lines. Wild type and 
mutated EGFR were exogenously transduced into Ba/F3 
cells. The sensitivity to EGFR-TKIs was evaluated by 
MTS assay with or without EGFR-TKIs.
Cell growth of Ba/F3 cells harboring classic EGFR 
mutations, exon 19 deletion (exon 19del) and L858R, was 
dramatically inhibited by afatinib (Figure 1A). Although 
less potent than afatinib, erlotinib effectively inhibited the 
proliferation of Ba/F3 cells. The potency of osimertinib 
was comparable to that of erlotinib, while rociletinib was 
less potent than erlotinib and osimertinib.
Erlotinib did not inhibit the proliferation of Ba/F3 
cells harboring EGFR T790M mutations, EGFR exon 
19del+T790M, and L858R+T790M, at low concentrations. 
However, afatinib and 3rd generation EGFR-TKIs, 
osimertinib and rociletinib, effectively inhibited the 
proliferation of Ba/F3 cells (Figure 1B).
In the clinic, skin rash, interstitial pneumonia, 
or diarrhea are common or life threatening side 
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effect of EGFR-TKIs. These side effects most 
likely due to the inhibition of the wild type EGFR 
expressed in the epithelial cells present in the skin, 
lungs, and gastrointestinal tract by EGFR-TKIs. Hence, 
EGFR-TKIs highly selective to mutated EGFR, but 
not to wild-type EGFR, can efficiently inhibit mutated 
EGFR in lung cancer cells without affecting the wild 
type EGFR expressed in epithelial cells. To evaluate 
Figure 1: Sensitivity of Ba/F3 cells harboring EGFR mutations to EGFR-TKIs. A. MTS assay for Ba/F3 cells harboring 
EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 
19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type 
EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars 
indicate standard deviation.
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the effect of EGFR-TKIs on the wild type EGFR, we 
performed an MTS assay in the presence of EGF and 
with or without EGFR-TKIs (Figure 1C). Ba/F3 cells 
were efficiently inhibited by afatinib. The IC50 value 
of afatinib was 31 nM, whereas those of the other three 
EGFR-TKIs were comparable, indicating that afatinib 
was the most potent EGFR-TKI against the wild type 
EGFR.
Immunoblotting was then performed to examine 
whether the aforementioned effect of EGFR-TKIs on 
Ba/F3 cells was exerted through inhibition of the EGFR 
signaling pathway (Figure 2).
In Ba/F3 cells harboring classic EGFR mutations, 
exon 19 deletions and L858R, afatinib dramatically 
inhibited the phosphorylation of EGFR, AKT, and 
ERK. Erlotinib and osimertinib comparably inhibited 
the phosphorylation of EGFR, AKT, and ERK. Erlotinib 
did not inhibit the phosphorylation of EGFR, AKT, and 
ERK in Ba/F3 cells harboring EGFR T790M mutations, 
exon 19del+T790M, and L858R+T790M. However, 
afatinib and 3rd generation EGFR-TKIs, osimertinib and 
rociletinib, effectively inhibited the phosphorylation of 
EGFR, AKT, and ERK. These data indicate that the 
sensitivity of Ba/F3 cells to EGFR-TKIs was mediated 
through inhibition of the EGFR and downstream 
signals.
Establishment of an in vitro model to determine 
the therapeutic window of EGFR-TKIs
The IC50 values of all EGFR-TKIs examined in this 
study are summarized in Figure 3A. Afatinib is reported 
to be ineffective against lung cancer harboring EGFR 
T790M positive mutations, because concentrations at 
which afatinib inhibits lung cancer cells harboring EGFR 
T790M are not achievable in humans due to dose limiting 
toxicities such as skin rash and diarrhea, indicating 
a narrow therapeutic window of afatinib for EGFR 
T790M [40].
To provide an estimation of the therapeutic 
window of EGFR-TKIs, we created an in vitro model 
by calculating the ratio of IC50 values of the wild type 
EGFR and mutated EGFR, referred to as the selectivity 
index (SI) (Figure 3B). In this model, the selectivity 
of each EGFR-TKI is high if the SI value is low. For 
Ba/F3 cells harboring classic EGFR mutations, exon 
19 deletions and L858R, afatinib showed the lowest 
SI values among EGFR-TKIs studied in this study, 
Figure 2: Inhibition of the phosphorylation of EGFR and downstream proteins by EGFR-TKIs in BaF3 cells harboring 
EGFR mutations. The results of immunoblotting for Ba/F3 cells with EGFR exon 19 deletion, L858R, exon 19 deletion+T790M, and 
L858R+T790M are shown. The cells were treated with the indicated concentrations of EGFR-TKIs for 4 h. Erlotinib, afatinib, osimertinib, 
and rociletinib were used as EGFR-TKIs. pEGFR, pAKT, and pERK indicate the phosphorylated form of EGFR, AKT, and ERK, 
respectively. Actin was used as a loading control.
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indicating a wide therapeutic window of afatinib for these 
mutations. Interestingly, for Ba/F3 cells harboring classic 
EGFR mutations, osimertinib showed mutation specificity 
similar to that of afatinib, and the SI values were around -2, 
indicating IC50 values for these classic mutations were 
about 100-fold lower than those for the wild-type EGFR.
For Ba/F3 cells harboring EGFR T790M, 
3rd generation EGFR-TKIs, osimertinib and rociletinib, 
showed striking mutation specificity. The SI values were 
around -2 or lower, indicating IC50 values for T790M 
mutation more than 100-fold lower than those for the 
wild-type EGFR. Unfortunately, erlotinib and afatinib did 
not demonstrate mutation specificity for EGFR T790M 
mutations. The SI values were more than zero, indicating 
that the IC50 values of erlotinib and afatinib for EGFR 
T790M mutations were higher than those for the wild-type 
EGFR.
To determine and to confirm the clinical relevance of 
this in vitro model, we reviewed the data of human clinical 
trials. The efficacy of erlotinib for classic EGFR mutations 
[41, 42] and inefficacy of erlotinib for T790M mutations are 
reported [24] and well accepted. Our in vitro model clearly 
indicated the difference of erlotinib efficacy for classic 
EGFR mutations and its inefficacy for T790M mutations. 
Again, the efficacy of afatinib for classic EGFR mutations 
[43] and its inefficacy for T790M mutations are reported 
[36]. Data from our in vitro model were in agreement with 
these results. The efficacy of osimertinib and rociletinib for 
patients with NSCLC harboring EGFR T790M mutation and 
little dose limiting toxicities have recently been described. 
The striking mutation specificity of osimertinib and 
rociletinib shown in the model matches well with the results 
of the reported trials. In summary, the results of our in vitro 
model match well with the reported clinical trials.
Figure 3: IC50 values and in vitro modeling. A. IC50 values (nM) of EGFR-TKIs for wild type and mutated EGFR are shown. 
Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. B. Calculated values of the selectivity index (SI) for EGFR 
mutations, exon 19 deletion, L858R, exon 19 deletion+T790M, and L858R+T790M. *; SI index >1.
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Figure 4: Sensitivity of lung cancer cell lines to EGFR-TKIs. A. MTS assay for PC-9, H3255, PC9-ER, and H1975 cells. The 
IC50 values (nM) for EGFR-TKIs are shown. Error bars indicate standard deviation. B. The results of immunoblotting for PC-9, H3255, 
PC9-ER, and H1975 cells are shown. The cells were treated with the indicated concentrations of EGFR-TKIs for 4 h. Erlotinib, afatinib, 
osimertinib, and rociletinib were used as EGFR-TKIs. pEGFR, pAKT, and pERK indicate the phosphorylated form of EGFR, AKT, and 
ERK, respectively. Actin was used as a loading control.
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Confirmation of the sensitivity/resistance profile 
of EGFR-TKIs in lung cancer cell lines
Furthermore, to confirm that the sensitivity/
resistance profile data from Ba/F3 stable cells are also 
observed in EGFR mutated human lung cancer derived 
cell lines, we performed MTS assay with or without 
EGFR-TKIs using human lung cancer derived cell lines 
(Figure 4A). The lung cancer cell lines used included 
PC-9 (EGFR exon 19del), H3255 (EGFR L858R), 
PC-9ER (EGFR exon 19 del+T790M), and H1975 (EGFR 
L858R+T790M).
The IC50 values of lung cancer cell lines are 
summarized in Table 1. For cell lines harboring classic 
EGFR mutations, exon 19 deletions (PC-9) and L858R 
(H3255), afatinib showed the most dramatic inhibitory 
effect. The calculated IC50 values of afatinib for PC-9 and 
H3255 were 0.8 nM and 0.3 nM, respectively. Although 
less potent than afatinib, erlotinib effectively inhibited the 
proliferation of lung cancer cells as previously described 
[20]. The calculated IC50 values of erlotinib for PC-9 
and H3255 were 7 nM and 12 nM, respectively. The 
potency of osimertinib was comparable to that of erlotinib. 
However, rociletinib was less potent than erlotinib and 
osimertinib. The calculated IC50 values of osimertinib for 
PC-9 and H3255 were 17 nM and 4 nM, respectively. The 
calculated IC50 values of rociletinib for PC-9 and H3255 
were 84 nM and 35 nM, respectively.
Erlotinib did not inhibit the proliferation of cell 
lines harboring EGFR T790M, PC-9ER and H1975, at 
low concentrations. However, afatinib and 3rd generation 
EGFR-TKIs, osimertinib and rociletinib, effectively 
inhibited the proliferation of lung cancer cells. The 
calculated IC50 values of afatinib, osimertinib, and 
rociletinib for PC-9ER were 165 nM, 13 nM, and 37 nM, 
respectively. The calculated IC50 values of afatinib, 
osimertinib, and rociletinib for H1975 were 57 nM, 5 nM, 
and 23 nM, respectively. These data indicate that the 
sensitivity/resistance profile data observed in Ba/F3 stable 
cells are similar to those observed in human lung cancer 
cell lines.
Furthermore, immunoblotting was performed to 
determine whether the aforementioned sensitivity of 
lung cancer cells to EGFR-TKIs was mediated through 
inhibition of the EGFR signaling pathway (Figure 4B). 
Consistent with the results of the MTS assay, afatinib 
most potently inhibited the phosphorylation of EGFR and 
downstream proteins, AKT and ERK, in PC-9 and H3255 
cells. Although less potent than afatinib, erlotinib and 
osimertinib effectively inhibited the phosphorylation of 
EGFR, AKT, and ERK in PC-9 and H3255. For the lung 
cancer cells harboring EGFR T790M, all EGFR-TKIs, 
but erlotinib, effectively inhibited the phosphorylation of 
EGFR, AKT, and ERK.
In summary, these data indicate that the sensitivity/
resistance profile observed in Ba/F3 cells was confirmed 
in human lung cancer cells.
Application of the in vitro model to EGFR  
exon 20 insertion mutations
Except for EGFR A763_Y764insFQEA, most 
of EGFR exon 20 insertion mutations are reported to 
be resistant to 1st generation EGFR-TKIs. Recently, the 
results of a clinical trial assessing afatinib treatment of 
patients with advanced NSCLC harboring uncommon 
EGFR mutations, including exon 20 insertion mutations 
have been reported [44]. Of the 23 NSCLC patients 
harboring EGFR exon 20 insertion mutations, only two 
(8.7%) patients presented an objective response, indicating 
the limited efficacy of afatinib for exon 20 insertion 
mutations.
Until now, there is no EGFR-TKI reported to be 
effective against exon 20 insertion mutations. To examine 
the sensitivity/resistance profile of EGFR exon 20 
insertion mutations to EGFR-TKIs, we performed MTS 
assays with or without EGFR-TKIs using cells harboring 
four representative EGFR exon 20 insertion mutations, 
namely, A763_Y764insFQEA, Y764_V765insHH, A767_
V769dupASV, and D770_N771insNPG (Figure 5A). 
Afatinib potently inhibited the growth of cells harboring 
EGFR A763_Y764insFQEA. Of the other three EGFR-
TKIs, osimertinib most effectively inhibited Ba/F3 cell 
growth.
Interestingly, for other 1st generation EGFR-TKIs 
resistant EGFR exon 20 insertion mutations, osimertinib 
and afatinib presented similar efficacy. The IC50 values 
of afatinib for Y764_V765insHH, A767_V769dupASV, 
and D770_N771insNPG were 134, 158, and 43 nM, 
Table 1: IC50 values (nM) of lung cancer cell lines
erlotinib afatinib rociletinib osimertinib
PC-9 (exon 19del) 7 0.8 84 17
H3255 (L858R) 12 0.3 35 4
PC-9ER (exon 19del+T790M) >10000 165 37 13
H1975 (L858R+T790M) 1185 57 23 5
BID007 (A763_Y764insFQEA) 45 8 1278 40
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Figure 5: Sensitivity of Ba/F3 cells harboring EGFR exon 20 insertion mutations to EGFR-TKIs. A. MTS assay for  
Ba/F3 cells harboring EGFR exon 20 insertion mutations. The mutations studied include A763_Y764insFQEA, Y764_V765insHH, A767_
V769dupASV, and D770_N771insNPG. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used 
as EGFR-TKIs. Error bars indicate standard deviation. B. IC50 values (nM) of EGFR-TKIs for EGFR exon 20 insertion mutations. C. The 
calculated values of the selectivity index (SI) for EGFR exon 20 insertion mutations are shown. *; SI index > 1.
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respectively. The IC50 values of osimertinib for 
Y764_V765insHH, A767_V769dupASV, and D770_
N771insNPG were 237, 333, and 42 nM, respectively 
(Figure 5B).
To estimate the therapeutic window of EGFR-
TKIs for EGFR exon 20 insertion mutations, we applied 
the aforementioned in vitro model to exon 20 insertion 
mutations (Figure 5C). Surprisingly, we found that 
osimertinib presented the lowest SI values of around −1, 
indicating IC50 values for EGFR exon 20 insertion 
mutations about 10 fold lower than those for the wild type 
EGFR. However, the SI values of other EGFR-TKIs were 
around or above zero. These data indicate that osimertinib 
may present a wide therapeutic window and is effective 
for several exon 20 insertion mutations.
Biological confirmation of osimertinib efficacy 
for lung cancer harboring EGFR exon 20 
insertion mutations
To biologically confirm the aforementioned efficacy 
of osimertinib for lung cancer harboring EGFR exon 
20 insertion mutations, further in vitro analyses were 
performed.
First, to confirm whether the above sensitivity pattern 
observed in Ba/F3 cells was also observed in human lung 
cancer cell lines, we performed immunoblotting and MTS 
assays using BID007 (EGFR A763_Y764insFQEA) cells 
(Figure 6A). To our knowledge BID007 is the only cell 
line harboring EGFR exon 20 insertion mutations, which 
we originally established [20]. The sensitivity pattern and 
inhibition of the phosphorylation of EGFR and downstream 
proteins were consistent with the results observed in 
Ba/F3 cells harboring EGFR A763_Y764insFQEA. The 
most dramatic inhibition of cell growth was observed with 
afatinib. The calculated IC50 value of afatinib for BID007 
was 8 nM. Although less potent than afatinib, erlotinib 
and osimertinib effectively inhibited the proliferation 
of BID007 cells. The calculated IC50 value of erlotinib 
and osimertinib for BID007 was 45 nM and 40 nM, 
respectively. However, rociletinib was less potent than 
erlotinib and osimertinib. The calculated IC50 value of 
rociletinib for BID007 was 1278 nM. These data indicate 
that the sensitivity pattern observed in Ba/F3 cells was also 
observed in human lung cancer cell line, BID007.
Next, to confirm that the sensitivity of Ba/F3 cells 
harboring EGFR exon 20 insertion mutations was exerted 
through inhibition of the EGFR signaling pathway, we 
performed immunoblotting (Figure 6B). As expected, 
for EGFR A763_Y764insFQEA, afatinib dramatically 
inhibited the phosphorylation of EGFR, AKT, and 
ERK. Erlotinib and osimertinib similarly inhibited the 
phosphorylation of EGFR, AKT, and ERK. For other 1st 
generation EGFR-TKIs resistant EGFR exon 20 insertion 
mutations, Y764_V765insHH, A767_V769dupASV and 
D770_N771insNPG, the inhibition of the phosphorylation 
of EGFR, AKT, and ERK was similar between osimertinib 
and afatinib.
Finally, to confirm the therapeutic window of 
osimertinib for 1st generation EGFR-TKIs resistant EGFR 
exon 20 insertion mutations, we performed apoptosis 
assays using Ba/F3 cells harboring wild type EGFR 
and EGFR D770_N771insNPG. We stained the Ba/F3 
cells with annexin V-APC and propidium iodide after 
48 h of EGFR-TKI treatment (0.1 μM). The proportion 
of annexin-V positive and/or propidium iodide positive 
cells was examined by flow cytometry (Figure 6C). 
As expected, afatinib induced apoptosis in both Ba/
F3 cells harboring wild type EGFR and EGFR D770_
N771insNPG, indicating a narrow therapeutic window of 
afatinib for EGFR D770_N771insNPG. The proportion 
of annexin-V positive cells was 82.5% for the wild type 
EGFR and 56.0% for EGFR D770_N771insNPG. In 
contrast, the effect of osimertinib on apoptosis in Ba/F3 
cells harboring wild type EGFR was low, while it was 
high in Ba/F3 cells harboring EGFR D770_N771insNPG. 
The proportion of annexin-V positive cells was 29.1% 
for the wild type EGFR and 48.6% for EGFR D770_
N771insNPG. These data indicate the wide therapeutic 
window of osimertinib for EGFR D770_N771insNPG.
In summary, we biologically confirmed the efficacy 
and therapeutic window of osimertinib for EGFR exon 
20 insertion mutations.
DISCUSSION
In this study, we compared the potency of erlotinib, 
afatinib, osimertinib, and rociletinib against multiple types 
of EGFR mutations such as classic EGFR mutations, exon 
19 deletions and L858R, with or without T790M, or exon 
20 insertion mutations. Because EGFR is ubiquitously 
expressed in epithelial cells, EGFR-TKIs induce toxicity 
when EGFR-TKIs affect the wild type EGFR in epithelial 
cells. Hence, the therapeutic window, i.e., the difference 
in term of the concentrations that affect the wild type and 
mutated EGFR, is important. In this study, we created an 
in vitro model to determine the therapeutic window of 
EGFR-TKIs by calculating the ratio of IC50 values of 
EGFR-TKIs in cells stably expressing the wild type EGFR 
or the mutated EGFR.
In general, the data from Ba/F3 stable cell lines and 
human lung cancer derived cell lines were consistent. For 
classic EGFR mutations, exon 19 deletions and L858R, 
afatinib was the most potent. Our data also showed a 
wide therapeutic window of afatinib for these mutations. 
However, in the clinic, the high frequency of adverse 
events such as skin rash or diarrhea is repeatedly reported 
[34, 35], indicating that the in vivo concentration of 
afatinib might exceed the concentration that inhibits the 
wild type EGFR. It is possible that, by reducing the dose, 
afatinib retains its ability to inhibit the mutated EGFR, but 
not the wild type EGFR.
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Figure 6: Efficacy of EGFR-TKIs for EGFR exon 20 insertion mutations. A. MTS assay (left) and immunoblotting (right) 
for BID007 (EGFR A763_Y764insFQEA) cells. Error bars indicate standard deviation. B. Results of immunoblotting for Ba/F3 cells with 
EGFR exon 20 insertion mutations. The cells were treated with the indicated concentrations of EGFR-TKIs for 4 h. Erlotinib, afatinib, 
osimertinib, and rociletinib were used as EGFR-TKIs. pEGFR, pAKT, and pERK indicate the phosphorylated form of EGFR, AKT, and 
ERK, respectively. Actin was used as a loading control. C. Apoptosis assay using cytometry. Ba/F3 cells harboring wild type EGFR 
and EGFR D770_N771insNPG (NPG) were treated with EGFR-TKIs for 48 h, subsequently the cells were stained with propidium iodide 
and annexin V-APC. The numbers indicate the proportion of annexin V-positive and/or propidium iodide-positive cells.
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For EGFR T790M positive mutations, osimertinib 
and rociletinib showed a strikingly potent inhibition 
compared to erlotinib or afatinib. In addition, osimertinib 
and rociletinib showed a wide therapeutic window for 
these mutations. These data indicate that osimertinib and 
rociletinib are effective and safe EGFR-TKIs for EGFR 
T790M positive mutations. In human clinical trials, 
osimertinib and rociletinib showed promising safety and 
efficacy, even though some hyperglycemia was observed 
in patients treated with rociletinib [38, 39].
Interestingly, for 1st generation EGFR-TKIs 
resistant exon 20 insertion mutations, Y764_V765insHH, 
A767V769dupASV, and D770_N771insNPG, osimertinib 
showed a similar potency and higher mutation specificity 
than afatinib. However, the IC50 values of osimertinib 
for these exon 20 insertion mutations are 10 to 100 fold 
higher than those for the classic EGFR mutations with or 
without T790M mutations. Thus, higher concentrations 
of osimertinib may be necessary to effectively treat the 
patients with 1st generation EGFR-TKIs resistant exon 20 
insertion mutations.
Preliminary pharmacokinetic profile, showing total 
plasma concentrations of osimertinib, was reported [30]. 
The mean plasma concentration of 6 patients treated with 
once-daily 20 mg oral osimertinib dosing in the AURA 
phase I study (NCT01802632) was around 100 nM, 
which is around the IC50 values found in this study for 
1st generation EGFR-TKIs resistant exon 20 insertion 
mutations (42–333nM). In addition, the results of this 
phase I study have been reported [38]. The patients were 
assigned to once-daily dosing from 20 mg to 240 mg. 
No dose-limiting toxicity was observed during the 
28-day evaluation period at any dose levels. Therefore, 
a maximum tolerated dose was not determined. The 
maximum serum concentrations were 106.3, 305.1, 635.4, 
1006, and 1510 nM for 20, 40, 80, 160, and 240 mg dose 
levels, respectively. These data indicate that osimertinib 
concentration may be adjusted to the level that effectively 
inhibits the mutant EGFR, but not the wild type EGFR. To 
examine the efficacy of osimertinib for NSCLC harboring 
1st generation EGFR-TKIs resistant exon 20 insertion 
mutations, dose adjusted clinical trials are anticipated.
From the EGFR-TKIs oriented viewpoint, erlotinib 
is effective for EGFR exon 19 deletions, L858R, and 
A763_Y764insFQEA. However, erlotinib does not seem 
to be effective for EGFR T790M positive mutations as 
previously described [20]. Afatinib seems to be effective 
and has a wide therapeutic window for EGFR exon 19 
deletion and L858R. However, afatinib was less potent 
than osimertinib and rociletinib for EGFR T790M positive 
mutations. Osimertinib and rociletinib showed a potent 
efficacy and a wide therapeutic window for EGFR T790M 
positive mutations.
Even for 3rd generation EGFR-TKIs, the potency 
spectrum was clearly different between osimertinib 
and rociletinib. Interestingly, for EGFR 19 deletion and 
L858R, osimertinib efficacy was comparable with that 
of erlotinib, indicating that osimertinib can be used for 
EGFR 19 deletion and L858R as first line EGFR-TKI. 
Furthermore, we identified the therapeutic window of 
osimertinib for 1st generation EGFR-TKIs resistant exon 
20 insertion mutations. The reason why osimertinib 
showed a distinct wide mutation spectrum is unknown. 
However, it may be partly due to the distinct chemical 
structure of this compound [30]. To our knowledge, this is 
the first report, which clearly demonstrates the difference 
in term of mutation spectrum of EGFR-TKIs against 
various types of EGFR mutations.
However, our study includes only in vitro study. 
The pharmacokinetics and pharmacodynamics may 
vary among EGFR-TKIs. Hence, EGFR-TKI in vivo 
concentrations may vary among EGFR-TKIs. To further 
develop a better strategy for using EGFR-TKIs, further in 
vivo and human clinical trials are mandatory.
In summary, we created an in vitro model to 
determine the therapeutic window of EGFR-TKIs, which 
matched well with the data obtained from human clinical 
trials. Interestingly, by applying the model, osimertinib 
showed the widest therapeutic window in relation to wild 
type EGFR for most mutations including EGFR exon 20 
insertion mutations. This model will provide a preclinical 
rationale for proper selection of EGFR-TKIs against 
clinically-relevant EGFR mutations.
MATERIALS AND METHODS
Cell lines
Five human NSCLC cell lines were used, namely, 
PC-9 [EGFR exon 19 deletion (delE746-A750)], H3255 
[EGFR L858R], PC-9ER [EGFR exon 19 deletion 
(delE746-A750)+T790M], BID007 [EGFR exon 20 
insertion (A763_Y764insFQEA)], and H1975 [EGFR 
L858R+T790M]. PC9 cells were a kind gift from Dr. Pasi 
Janne (Dana-Farber Cancer Institute, Boston, MA, USA). 
H3255 and H1975 were purchased from the American 
Type Culture Collection (Manassas, VA, USA). PC-9ER 
cells become resistant to erlotinib after chronic exposure 
to erlotinib through acquisition of EGFR T790M second 
mutation. BID007 was originally established [20]. Cell 
authentication for H1975 and H3255 was performed in 
June 2015.
Reagents
Erlotinib and afatinib were purchased from LC 
Laboratories (Woburn, MA, USA). Osimertinib and 
rociletinib were purchased from Selleck Chemicals 
(Houston, TX, USA). Total EGFR antibody (#2232), 
total AKT antibody (#9272), phospho-AKT (S473; D9E) 
antibody (#4060), total p44/42 MAPK antibody (#9102S), 
and phospho-p44/42 MAPK (T202/204) antibody 
Oncotarget38800www.impactjournals.com/oncotarget
(#9101S) were purchased from Cell Signaling Technology 
(Beverly, MA, USA). Phospho-EGFR (Y1068) 
antibody (44788G) was purchased from Invitrogen/Life 
Technologies (Carlsbad, CA, USA). Actin antibody was 
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Ba/F3 stable cell lines
Ba/F3 cells stably expressing the wild type and 
mutated EGFR were created as previously described [20]. 
Ba/F3 cells harboring EGFR mutations were cultured in 
RPMI-1640 growth medium, supplemented with 10% fetal 
bovine serum at 37°C in a humidified 5% CO
2
 incubator. 
Ba/F3 cells expressing EGFR wild type were cultured in 
RPMI-1640 growth medium, supplemented with 10% 
fetal bovine serum at 37°C in a humidified 5% CO
2
 
incubator with EGF (10 ng/mL). The EGFR mutations 
examined in this study include delL747_P753insS 
(exon 19del), L858R, delL747_P753insS+T790M (exon 
19del+T790M), L858R+T790M, A763_Y764insFQEA, 
Y764_V765insHH, A767_V769dupASV, and D770_
N771insNPG.
Cell proliferation assay
The MTS assay was performed as previously 
described [20]. PC-9, H3255, PC-9ER, H1975, and 
BID007 were seeded in 96-well plates. Twenty-four 
hours after seeding, the appropriate medium with or 
without EGFR-TKI was added to each well. Control cells 
were treated with the same concentration of the vehicle, 
dimethyl sulfoxide (DMSO). Seventy-two hours after 
treatment, absorbance was measured.
For Ba/F3 cells, the cells were seeded with or 
without EGFR-TKI. Seventy-two hours after seeding, 
absorbance was measured. All experiments were 
performed at least three times.
Immunoblotting analysis
Cells were treated with EGFR-TKI at concentrations 
of 0.01–1 μmol/L for 4 h. Cells were lysed in Cell Lysis 
Buffer (Cell Signaling Technology). Equal amounts of 
protein were loaded per lane on sodium dodecyl sulfate-
polyacrylamide gels. Separated proteins were transferred 
to polyvinylidene fluoride membranes. The membranes 
were incubated overnight with primary antibodies at 4°C 
and then incubated with secondary antibodies for 1 h. For 
the detection of proteins, the membranes were incubated 
with agitation in LumiGLO reagent and peroxide (Cell 
Signaling Technology) and then exposed to X-ray film.
Apoptosis assay
Ba/F3 cells harboring wild type EGFR and EGFR 
D770_N771insNPG were seeded in 6-well plates. The 
cells were treated with EGFR-TKIs (0.1 μM) for 48 h. 
Control cells were treated with the same concentration 
of the vehicle, DMSO. We analyzed the apoptotic status 
of cells using the Annexin V Apoptosis Detection Kit 
APC (eBioscience, San Diego, CA, USA) according to 
the manufacturer’s protocol. The proportion of apoptotic 
cells was evaluated by flow cytometric analysis, using the 
Gallios flow cytometer system (Beckman Coulter, Brea, 
CA, USA).
Statistical analysis
Statistical analysis was performed using the 
GraphPad Prism software, version 4.0 (GraphPad 
Software, La Jolla, CA, USA). IC
50
 was calculated by 
using the GraphPad Prism software.
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